Arcutis Biotherapeutics Inc

ARQT

Add to Watchlist

21.320USD

-0.250-1.16%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Arcutis Biotherapeutics Inc's Score

Industry at a Glance

Industry Ranking

27 / 155

Overall Ranking

87 / 4482

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Arcutis Biotherapeutics Inc Highlights

StrengthsRisks

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 530.93% year-on-year.

Undervalued

The company’s latest PE is -1389.83, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 133.41M shares, decreasing 5.32% quarter-over-quarter.

Held by Paul Tudor Jones

Star Investor Paul Tudor Jones holds 106.13K shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

34.625

Target Price

+60.52%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Arcutis Biotherapeutics Inc is 8.54, ranking 52 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 105.40M, representing a year-over-year increase of 60.07%, while its net profit experienced a year-over-year increase of 54.93%.

Score

Industry at a Glance

Previous score

8.54

Change

0



Financials

6.18

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.87

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Arcutis Biotherapeutics Inc is 7.12, ranking 93 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -1389.83, which is -99.97% below the recent high of -0.42 and -1.74% above the recent low of -1413.95.

Score

Industry at a Glance

Previous score

7.12

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 27/155

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Arcutis Biotherapeutics Inc is 8.25, ranking 48 out of 155 in the Pharmaceuticals industry. The average price target is 30.50, with a high of 37.00 and a low of 29.00.

Score

Industry at a Glance

Previous score

8.25

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Arcutis Biotherapeutics Inc is 7.11, ranking 51 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 23.90 and the support level at 19.33, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.16

Change

-0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Arcutis Biotherapeutics Inc is 10.00, ranking 1 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 106.66%, representing a quarter-over-quarter decrease of 11.87%. The largest institutional shareholder is PRFDX, holding a total of 1.06M shares, representing 0.85% of shares outstanding, with 9545.45% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Suvretta Capital Management, LLC

11.96M

+14.18%

Frazier Life Sciences Management, L.P.

9.87M

--

Rubric Capital Management LP

8.27M

-23.05%

BlackRock Institutional Trust Company, N.A.

7.99M

+5.38%

State Street Investment Management (US)

5.49M

+18.25%

Polar Capital LLP

5.56M

+4.86%

Jennison Associates LLC

6.76M

-44.85%

Gilder Gagnon Howe & Co. LLC

4.45M

+0.56%

Morgan Stanley & Co. LLC

3.98M

+0.89%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Arcutis Biotherapeutics Inc is 5.61, ranking 63 out of 155 in the Pharmaceuticals industry. The company's beta value is 1.55. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Arcutis Biotherapeutics Inc

ARQT

7.84 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

9.11 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

8.59 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

8.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment